Do you want to read an article? Please log in or register.
Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis
Interstitial Lung DiseasePulmonary Fibrosis
Related content
RECOMMENDED
Pulmonary Fibrosis
Real-World Clinical Effectiveness and Safety of Antifibrotics in Progressive Pulmonary Fibrosis Associated with Rheumatoid Arthritis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Narváez J, Aguilar-Coll M, Vicens-Zygmunt V, Alegre JJ, Bermudo G, Molina-Molina M
doi: 10.3390/jcm13237074
Pulmonary Fibrosis
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Adv Ther
Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T
doi: 10.1007/s12325-024-03079-2
RECOMMENDED
Pulmonary Fibrosis
Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respirology
Platenburg MGJP, Nakshbandi G, Moor CC, van Batenburg AA, Mostard RLM, Voortman M, Moonen L, Hekelaar N, Overbeek MJ, Bogaarts B, Kramer H, Marges E, Boerrigter BB, Bresser P, Schakenraad E, van der Maten J, van der Sloot CA, Walen S, Afonso PM, Wijsenbeek MS, Grutters JC
doi: 10.1111/resp.70030
Pulmonary Fibrosis
Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study
Chron Respir Dis
Carlson L, Kalafatis D, Pesonen I, Magnusson JM, Skold M
doi: 10.1177/14799731241299443
Pulmonary Hypertension
Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan
Adv Ther
Vizza CD, Klok R, Harley J, Small M, Scott M, Lautsch D, White RJ
doi: 10.1007/s12325-024-03026-1
Pulmonary Fibrosis
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Respir Med
Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V
doi: 10.1016/j.rmed.2025.108221
Pulmonary Hypertension
A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension
Respir Med
Paoli CJ, Zhang C, Tang X, Panjabi S, Thompson A, El-Kersh K
doi: 10.1016/j.rmed.2025.108112
RECOMMENDED
Pulmonary Fibrosis
Effect of Admilparant, an LPA1 Antagonist, on Disease Progression in Pulmonary Fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest
Kreuter M, Maher TM, Wuyts WA, Valenzuela C, Hamblin M, Kim S, Patel A, Elpers B, Richeldi L
doi: 10.1016/j.chest.2025.04.003
Lung Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762